# 2025-06878: NIH Grants Exclusive License for Brain-Targeting Nano-Drug Tech Platform

2025-06878, Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2025-04-22, effective Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered.; PRIA reads it as touching household money (as of 2026-10-12).

- Canonical: https://policyrisk.com/federal-register/2025-06878
- As of: 2026-10-12
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-06878
- Title: Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 90 FR 16878
- Published: 2025-04-22
- Effective: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-12

## In one line

NIH Grants Exclusive License for Brain-Targeting Nano-Drug Tech Platform

## Summary

The National Cancer Institute plans to give Sangam Lifesciences an exclusive license to use a new drug delivery technology that targets the brain and lymphatic system based on molecule size. This could speed up better treatments for diseases affecting these areas. Interested parties must send comments or license requests by April 22, 2025, or miss out on this opportunity.

## Abstract

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the Supplementary Information section of this notice to Sangam Lifesciences, Inc. (Sangam), a company located in Denver, Colorado.

## Effects PRIA read

- Exclusive License Contemplated for Sangam: benefit, medium. The National Cancer Institute is contemplating granting Sangam Lifesciences, Inc. an exclusive patent license to practice the listed inventions. The prospective exclusive license territory may be worldwide and would be royalty-bearing and limited to development, manufacture, and commercialization o…
- Exclusivity Limited to Cancer Use: cost, medium. The scope of exclusivity, if granted, will be limited to the PLS-alpha-galactosylceramide prodrug for the treatment of cancers. The notice explicitly states that other fields of use would remain available, including use of the PLS prodrug for non-oncology indications and PLS conjugated to other the…
- April 22, 2025 Application Deadline: cost, low. Only written comments and/or license applications received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered. Interested parties who do not submit by that date may not be able to file timely objections or license applications in response to…
- Application Confidentiality and Objection Rules: cost, medium. Complete license applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information. Comments or objections that are not in the form of a license application will not be treated confidentially and may be made public…

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2025-06878 on federalregister.gov](https://www.federalregister.gov/documents/2025/04/22/2025-06878/prospective-grant-of-an-exclusive-patent-license-size-dependent-brain-and-lymphatic-distribution-of)
- [2025-06878 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-04-22/pdf/2025-06878.pdf)

## Related
- [Previous: 2025-06876, Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible…](https://policyrisk.com/federal-register/2025-06876)
- [Next: 2025-06879, National Center for Advancing Translational Sciences; Notice of Closed Meeting](https://policyrisk.com/federal-register/2025-06879)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-06878 (as of 2026-10-12).
